##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 159 Download : 84

##plugins.themes.academic_pro.article.main##

Abstract

The place of traditional sulfonylurea (SM) drugs that stimulate insulin secretion began to be occupied by incretin drugs , primarily dipeptidyl peptidase-4 (iDPP-4) inhibitors, due to their unique physiological glucose-dependent effect on the secretion of insulin and glucagon, allowing effective control of diabetes mellitus (DM) . ) 2 types without significant side effects. Drugs of the DPP-4 class are recommended for use at all stages of the development of diabetes, starting from the onset, both in monotherapy and in combination with oral hypoglycemic drugs (PSP) and insulin. Cardiovascular safety, the ability to take in the late stages of chronic kidney disease (CKD), a neutral effect on body weight, ease of use are their undeniable advantages. The combination of iDPP-4 (for example, vildagliptin ) with metformin is the most popular, covers the vast majority of pathophysiological defects in type 2 diabetes, is available in a fixed form (for example, Galvus Met). More than 10 years of experience in clinical practice with drugs of the DPP-4 class (for example, Galvus) suggests that their main clinical effects have been finally identified, they can be systematized and the established advantages and disadvantages in the management of type 2 diabetes can be discussed.


 

Keywords

diabetes mellitus, incretins , iDPP-4 , vildagliptin , metformin

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Tazhibaeva I.A., & Yusupova Sh.K. Scientific supervisor. (2022). Pharmacotherapy of IDPP 4: benefits of modern diabetes management. Texas Journal of Medical Science, 14, 147–152. https://doi.org/10.62480/tjms.2022.vol14.pp147-152
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet.352( 9131):837-853. doi : 10.1016/S0140-6736(98)07019-6
  2. Turner RC, Holman RR. Lessons from UK prospective diabetes study. Diabetes research and clinical practice.28:S151-S157. doi : 10.1016/0168-8227(95)01105-M
  3. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine. 1993 ;329 (14):977-986. doi : doi:10.1056/NEJM199309303291401
  4. Ahluwalia R, Vora J. Emerging role of insulin with incretin therapies for management of type 2 diabetes. Diabetes Therapy. 2011 ;2 (3):146-161. doi: 10.1007/s13300-011-0005-0
  5. Rizos EC, Ntzani EE, Papanas N, et al. Combination Therapies of DPP4 inhibitors and GLP1 Analogues with Insulin in Type 2 Diabetic Patients:A Systematic Review. Curr Vasc Pharmacol . 2013 ;11 (6):992-1000. doi : 10.2174/15701611113119990103
  6. Schweizer A, Dejager S, Foley JE. Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin . Diabetes Therapy. 2012 ;3 (1):8. doi : 10.1007/s13300-012-0008-5
  7. Fonseca V, Dejager S, Albrecht D, et al. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM). diabetes. 2006;55( suppl 1): p . A 111. Abstract 467- P
  8. Dedov I.I., Shestakova M.V. Diabetes mellitus in the elderly: diagnosis, clinic, treatment: A practical guide for physicians. – M; 2011. [ Dedov II, Shestakova MV. Sakharnyy diabetes v pozhilom vozraste : diagnostika , klinika , lechenie : Prakticheskoe leadership dlya vrachey . Moscow; 2011.]
  9. European Medicines Agency. Concept paper on the need for revision of the note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus, 2008. [Electronic resource]. URL: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003182.pdf (accessed 16.04.2017).
  10. Mathieu C., Kozlovsky P., Foley JE et al. Clinical Safety and tolerability of vildagliptin — insights from randomized trials, observational studies and post-marketing surveillance // European Endocrinology. 2017 Vol . 13(2). P. 68–72.
  11. Galstyan G.R. Cardiovascular effects of i-DPP-4 from the point of view of evidence-based medicine. TECOS: many answers, are there any questions left // Effective pharmacotherapy. 2015. No. 4(32). pp. 38–44 [ Galstyan GR Kardiovascular ehffekty i-DPP- 4s tochki zreniya prover'noj medicine . TECOS: many otvetov , ostalis ' li voprosy // EHffektivnaya farmakoterapiya . 2015. No. 4(32). S. 38–44 (in Russian)].
  12. AZ Solijonovna. The process of national and spiritual democracy of the personal socialization and its functions// Hunan Daxue Xuebao/Journal of Hunan University Natural Sciences// Vol. 48. No. 12. 湖南大学学报 (自然科学版), 2021. Pages 1565-1571. https://johuns.net/index.php/abstract/239.html
  13. Solijonovna, Z. A. (2020). Modern Information Technologies - A Factor Of Increasing Youth Education, Potential And Spirituality. The American Journal of Social Science and Education Innovations, 2(09), 554-560. https://doi.org/10.37547/tajssei/Volume02Issue09-83
  14. Aripova, Z. S. Informatizing society as one of the reasons for creating a global society / Z. S. Aripova, A. A. Aysachev // Экономика и социум. – 2021. – No 4-1(83). – P. 62-65.
  15. Aripova, Z. S. Cultural traditions: their essence and structure / Z. S. Aripova // Экономика и социум. – 2020. – No 5-1(72). – P. 16-19.
  16. Aripova, Z. S. Essence and life meaning of world view / Z. S. Aripova // Экономика и социум. – 2020. – No 11(78). – P. 78-81.
  17. Aripova, Z. S. Philosophy as a unity of scientific and non-scientific knowledge / Z. S. Aripova // Экономика и социум. – 2022. – No 3-2(94). – P. 46-49. – EDN MIJHSE.